Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 5448-5458, October 1, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagy, J. A.
Right arrow Articles by Dvorak, H. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagy, J. A.
Right arrow Articles by Dvorak, H. F.

Exchange of Macromolecules between Plasma and Peritoneal Cavity in Ascites Tumor-bearing, Normal, and Serotonin-injected Mice1

Janice A. Nagy2, Kemp T. Herzberg, Elizabeth M. Masse, Gary P. Zientara and Harold F. Dvorak

Departments of Pathology, Beth Israel Hospital and Harvard Medical School and the Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215 [J.A.N., K.T.H., E.M.M., H.F.D.], and the Francis Bitter National Magnet Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [G.P.Z.]

Fluorescein-labeled dextrans (FITC-D) from 3 to 5000 kDa (Stokes' radii from 1 to 40 nm) were used to study influx from the plasma into the peritoneum and efflux from the peritoneal cavity into the plasma in normal and ascites tumor-bearing mice and in mice whose peritoneal vessels had been rendered hyperpermeable by serotonin. Two syngeneic transplantable murine ascites tumors were studied: mouse ovarian tumor and the TA3/St breast adenocarcinoma. To control for effects of peritoneal fluid volume, influx and efflux were also analyzed in mice that had received 5 ml of 5% bovine serum albumin i.p. as "artificial ascites." Following i.v. or i.p. injection, levels of FITC-D in the plasma and peritoneal fluid were quantitated by fluorimetry at successive time intervals from 5 to 360 min posttracer injection. Influx and efflux data were analyzed with a model consisting of three compartments (plasma, peritoneal cavity, and the extravascular space of all other organs) to yield kinetic parameters that characterized macromolecular transport. Depending on the size of the FITC-D tracer, from 3- to 50-fold more FITC-D accumulated in mouse ovarian tumor or TA3/St tumor ascites fluid, and 3- to 10-fold more FITC-D accumulated in the peritoneum of serotonin-treated than normal mice, all of it intact by gel exclusion chromatography. Influx of the FITC-D from plasma into the peritoneum, as characterized by the rate constant k1, was 2- to 40-fold greater in ascites tumor-bearing animals and 2- to 10-fold greater in serotonin-treated animals than in controls. Control animals with artificial ascites showed at most a 4-fold increase in the value of k1. As judged by fluorescence microscopy, the permeability of peritoneal-lining vessels in ascites tumor-bearing animals was greatly increased to FITC-D of 70 to 5000 kDa. Efflux of FITC-D, characterized by the rate constant k2, was reduced from 5- to 50-fold in ascites tumor-bearing animals but was unchanged or actually somewhat enhanced following serotonin treatment. Efflux in animals that had received artificial ascites was reduced 2.5- to 12.5-fold, correlating increased peritoneal fluid volume with decreased efflux. We conclude that tracer accumulation in malignant ascites fluid results from both increased influx as well as impaired efflux. Influx, and to a lesser extent efflux, were significantly affected by tracer size. However, within the range of FITC-D tested, we found no absolute size barrier to macromolecular transport from plasma to the peritoneal cavity, or vice versa. Our results may aid in the design of therapeutic macromolecules whose properties favor their escape from tumor vessels and their accumulation in tumor ascites.

1 This work was supported by NIH Research Grant CA-28471 and under terms of a contract from the National Foundation for Cancer Research.

2 To whom requests for reprints should be addressed, at Department of Pathology, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215.

Received 10/21/88. Revised 4/21/89. Accepted 6/23/89.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. Rippe, C. Rippe, K. Sward, and B. Rippe
Disproportionally low clearance of macromolecules from the plasma to the peritoneal cavity in a mouse model of peritoneal dialysis
Nephrol. Dial. Transplant., January 1, 2007; 22(1): 88 - 95.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Milliken, C. Scotton, S. Raju, F. Balkwill, and J. Wilson
Analysis of Chemokines and Chemokine Receptor Expression in Ovarian Cancer Ascites
Clin. Cancer Res., April 1, 2002; 8(4): 1108 - 1114.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. J. Bayless, R. Salazar, and G. E. Davis
RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the {alpha}v{beta}3 and {alpha}5{beta}1 Integrins
Am. J. Pathol., May 1, 2000; 156(5): 1673 - 1683.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. J. Lim, D. Masin, T. D. Madden, and M. B. Bally
Influence of Drug Release Characteristics on the Therapeutic Activity of Liposomal Mitoxantrone
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 566 - 573.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.